TriangleNCT00577512 · REGISTRY CONDITION SEARCH
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2017-11-20
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients with multiple myeloma, treated or untreated, with the presence of one or more of the high risk features as defined below. High risk by gene expression profiling at any time prior to enrollment: 1. PROLIFERATION signature, MMSET/FGFR3, c-MAF/MAF-B gene groups or 2. High risk score based on University of Arkansas Myeloma Institute for Research and Therapy (MIRT) 70 gene model. * Abnormal metaphase cytogenetics at any time prior to enrollment, or * Lactate Dehydrogenase (LDH) \> 250 IU/L (upper limit normal) at any time prior to enrollment * Zubrod ≤ 2, unless due to symptoms of MM. * Patients must be \< 75 years of age at the time of registration. * Patient must have signed an Institutional Review Board (IRB)-approved informed consent and understand the investigational nature of the study. * Negative serology for HIV. * Patients must not have a history of chronic obstructive or chronic restrictive pulmonary disease. Patients must have adequate pulmonary function studies \> 50% of predicted on mechanical aspects (FEV1, forced vital capacity (FVC), etc) and diffusion capacity (DLCO) \> 50% of predicted. Patients unable to complete pulmonary function tests because of myeloma-related chest pain, must have a high resolution CT scan of the chest and must also have acceptable arterial blood gases defined as P02 greater than 70. * Patients with recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias are ineligible. Ejection fraction by echocardiogram (ECHO) or must be \> 40% and must be performed within 60 days prior to registration, unless the patient has received chemotherapy within that period of time (dexamethasone and thalidomide excluded), in which case the left ventricular ejection fraction (LVEF) must be repeated. * No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. Prior malignancy is acceptable provided there has been no evidence of disease within the three-year interval or if the malignancy is considered much less life threatening than the myeloma. * Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. * Patients must be able to receive full doses of HD-DTPACE, in the opinion of the treating investigator, with the exception that patients with serum creatinine \> 1.5 mg/dL will receive modified doses of cisplatin. Exclusion Criteria: * Fever or active infection requiring intravenous antibiotics within 72 hours from baseline. * Liver function abnormalities with total bilirubin more than twice the upper limit of normal or aspartate amino transferase (AST)/alanine amino trasferase (ALT) more than three times the upper limit of normal. * Severe renal dysfunction, defined as a creatinine \> 3mg/dl or a creatinine clearance of \<30ml/min. * Platelet count \< 30,000/mm3, or absolute neutrophil count (ANC) \< 1,000/μl. * Clinically significant hepatic dysfunction as noted by direct bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis. * New York Hospital Association (NYHA) Class III or Class IV heart failure. * Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol. * Prior adriamycin exposure \> 450 mg/m2.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- DTPACE
- intervention Names
- Drug: DTPACE
- label
- HD DTPACE
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- HD DTPACE
- description
- * Dexamethasone 200 mg Intravenous Infusion "Piggy-Back" (IVPB) Days 1-7 * Thalidomide 200 mg by mouth (PO) Days 1-7 * Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency) * Adriamycin 15 mg/m2 Days 1-4 * Cyclophosphamide 600 mg/m2 Days 1-4 * Etoposide 60 mg/m2 Days 1-4
- name
- DTPACE
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 4
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Complete Response (CR) defined as all of the following for a minimum of 2 months: a) absence of urine and serum M-components by immunofixation; b) bone marrow should be adequately cellular (\>20%); c) normal serum calcium; d) no new bone lesions or enlargement of existing lesions. Near Complete Response included all elements of CR except immunofixation studies remained positive.
- measure
- Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer.
- time Frame
- 12 months
Full study description
- brief Summary
- This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses closer together (before the myeloma comes back or gets worse), subjects in this study will have better outcomes.
- detailed Description
- This study has the following goals: * To find out how many subjects treated with high dose DTPACE (Dexamethasone, Thalidomide, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide. (HD DTPACE) on this protocol will have a complete response or near complete response that lasts for 6 months or longer. * In subjects achieving a response, to find out how long the response will last. * To learn more about the side effects of this treatment. Up to 75 subjects, male or female, age 18 and older, regardless of race or ethnicity, will participate in this study at the University of Arkansas for Medical Sciences (UAMS) only. The treatment in this study is divided into 3 parts * High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored. * High dose DTPACE and stem cell re-infusion. * Velcade, Thalidomide, Dexamethasone (sometimes known as VTD) Maintenance therapy.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-9b12934004b1e6149a3f
- requested nct id
- NCT00577512
- primary nct id
- NCT00577512
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- 842b4d5cd0e7b843ef4d31ff14ad71e08bced002f0447f0ae5aa89bd2653b74b
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-9b12934004b1e6149a3f
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00577512
- occurrences
- context exact
- NCT00577512
- end
- 11
- exact text
- NCT00577512
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/986/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 0a1575827226607d60df7a69f216c2a523e431c71f5720a19a22c3f4e0c14158
Preserved source evidence · Not medical advice